Leerink Partnrs Predicts Lower Earnings for Inari Medical

Inari Medical, Inc. (NASDAQ:NARI) – Investment analysts at Leerink Partnrs lowered their Q1 2025 EPS estimates for Inari Medical in a research note issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn $0.02 per share for the quarter, down from their previous forecast of $0.03. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.77) per share. Leerink Partnrs also issued estimates for Inari Medical’s FY2025 earnings at $0.18 EPS and FY2026 earnings at $0.29 EPS.

Several other research analysts have also issued reports on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Inari Medical in a research report on Friday, August 9th. They issued a “buy” rating and a $68.00 price target for the company. Truist Financial raised their price objective on shares of Inari Medical from $46.00 to $50.00 and gave the stock a “hold” rating in a report on Tuesday, October 29th. Wells Fargo & Company dropped their price objective on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Finally, Robert W. Baird raised their price objective on shares of Inari Medical from $66.00 to $67.00 and gave the stock an “outperform” rating in a report on Tuesday, October 29th. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $58.89.

Inari Medical Stock Up 0.4 %

NASDAQ:NARI opened at $51.03 on Wednesday. Inari Medical has a 12-month low of $36.73 and a 12-month high of $67.13. The firm has a market capitalization of $2.99 billion, a PE ratio of -37.65 and a beta of 0.96. The firm has a 50-day moving average price of $45.86 and a 200 day moving average price of $47.43.

Insider Activity

In other Inari Medical news, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $45.83, for a total value of $1,833,200.00. Following the transaction, the director now directly owns 643,296 shares of the company’s stock, valued at approximately $29,482,255.68. This trade represents a 5.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Mitch C. Hill sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the transaction, the chief financial officer now directly owns 179,600 shares in the company, valued at approximately $8,105,348. The trade was a 1.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 186,000 shares of company stock valued at $8,990,990 over the last three months. 10.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Inari Medical

Hedge funds and other institutional investors have recently made changes to their positions in the company. Lighthouse Investment Partners LLC bought a new position in shares of Inari Medical during the second quarter worth $2,145,000. Aigen Investment Management LP bought a new position in shares of Inari Medical during the third quarter worth $428,000. Integral Health Asset Management LLC boosted its position in shares of Inari Medical by 100.0% during the second quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company’s stock worth $19,260,000 after purchasing an additional 200,000 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Inari Medical by 63.2% during the third quarter. Jennison Associates LLC now owns 1,576,641 shares of the company’s stock worth $65,021,000 after purchasing an additional 610,468 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Inari Medical by 1,219.9% during the second quarter. The Manufacturers Life Insurance Company now owns 394,901 shares of the company’s stock worth $19,014,000 after purchasing an additional 364,983 shares in the last quarter. 90.98% of the stock is owned by institutional investors.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.